<font color="blue">Effect_1</font> of <font color="blue">rosuvastatin_1</font> <font color="blue">monotherapy_1</font> or <font color="blue">in_1</font> <font color="blue">combination_1</font> <font color="blue">with_1</font> <font color="blue">fenofibrate_1</font> or <font color="blue">ω-3_1</font> <font color="blue">fatty_1</font> <font color="blue">acids_1</font> on <font color="blue">lipoprotein_2</font> <font color="blue">subfraction_2</font> <font color="blue">profile_2</font> <font color="blue">in_1</font> <font color="blue">patients_1</font> <font color="blue">with_2</font> <font color="blue">mixed_2</font> <font color="blue">dyslipidaemia_2</font> <font color="blue">and_1</font> <font color="blue">metabolic_2</font> <font color="blue">syndrome_2</font> <font color="blue">._2</font> <font color="blue">
<br>
<br>_1</font> BACKGROUND <font color="blue">Raised_1</font> <font color="blue">triglycerides_1</font> <font color="blue">(_1</font> <font color="blue">TG_1</font> <font color="blue">)_1</font> , <font color="blue">decreased_1</font> <font color="blue">high_2</font> <font color="blue">-_2</font> <font color="blue">density_2</font> <font color="blue">lipoprotein_2</font> <font color="blue">cholesterol_2</font> <font color="blue">(_2</font> <font color="blue">HDL_2</font> <font color="blue">-_2</font> <font color="blue">C_2</font> <font color="blue">)_2</font> <font color="blue">levels_2</font> and <font color="blue">a_1</font> <font color="blue">predominance_1</font> <font color="blue">of_1</font> <font color="blue">small_1</font> <font color="blue">dense_1</font> <font color="blue">low_1</font> <font color="blue">density_1</font> <font color="blue">lipoproteins_1</font> <font color="blue">(_1</font> <font color="blue">sdLDL_1</font> <font color="blue">)_1</font> are <font color="blue">characteristics_1</font> of <font color="blue">the_1</font> <font color="blue">metabolic_2</font> <font color="blue">syndrome_2</font> <font color="blue">(_2</font> <font color="blue">MetS_2</font> <font color="blue">)_2</font> <font color="blue">._2</font> <font color="blue">
<br>_1</font> OBJECTIVE <font color="blue">To_1</font> <font color="blue">compare_1</font> <font color="blue">the_1</font> <font color="blue">effect_1</font> <font color="blue">of_1</font> <font color="blue">high_1</font> <font color="blue">-_1</font> <font color="blue">dose_1</font> <font color="blue">rosuvastatin_1</font> <font color="blue">monotherapy_1</font> <font color="blue">with_1</font> <font color="blue">moderate_1</font> <font color="blue">dosing_1</font> combined <font color="blue">with_1</font> <font color="blue">fenofibrate_1</font> or <font color="blue">ω-3_1</font> <font color="blue">fatty_1</font> <font color="blue">acids_1</font> <font color="blue">on_1</font> <font color="blue">the_1</font> <font color="blue">lipoprotein_2</font> <font color="blue">subfraction_2</font> <font color="blue">profile_2</font> <font color="blue">in_1</font> <font color="blue">patients_1</font> <font color="blue">with_2</font> <font color="blue">mixed_2</font> <font color="blue">dyslipidaemia_3</font> <font color="blue">and_2</font> <font color="blue">MetS._3</font> 
<br> METHODS We previously randomised patients with <font color="blue">low_2</font> <font color="blue">-_2</font> <font color="blue">density_2</font> <font color="blue">lipoprotein_2</font> <font color="blue">cholesterol_2</font> <font color="blue">(_2</font> <font color="blue">LDL_2</font> <font color="blue">-_2</font> <font color="blue">C_2</font> <font color="blue">)_2</font> > 160 and TG > 200   mg / dl to <font color="blue">rosuvastatin_1</font> <font color="blue">monotherapy_1</font> 40   mg / day ( R group , n = 30 ) or <font color="blue">rosuvastatin_1</font> 10 mg / day <font color="blue">combined_1</font> <font color="blue">with_1</font> <font color="blue">fenofibrate_1</font> 200 mg / day ( RF group , n = 30 ) <font color="blue">or_1</font> <font color="blue">ω-3_1</font> <font color="blue">fatty_1</font> <font color="blue">acids_1</font> 2 g / day ( Rω group , n = 30 ) . In the <font color="blue">present_1</font> <font color="blue">study_1</font> <font color="blue">,_1</font> <font color="blue">only_1</font> <font color="blue">patients_1</font> <font color="blue">with_1</font> <font color="blue">MetS_2</font> <font color="blue">were_1</font> <font color="blue">included_1</font> ( 24 , 23 and 24 in the R , RF and Rω groups respectively ) . <font color="blue">At_1</font> <font color="blue">baseline_1</font> and <font color="blue">after_1</font> <font color="blue">12_1</font> <font color="blue">weeks_1</font> <font color="blue">of_1</font> <font color="blue">treatment_1</font> <font color="blue">,_1</font> <font color="blue">the_1</font> <font color="blue">lipoprotein_2</font> <font color="blue">subfraction_2</font> <font color="blue">profile_2</font> <font color="blue">was_1</font> <font color="blue">determined_2</font> <font color="blue">by_2</font> <font color="blue">polyacrylamide_2</font> <font color="blue">3%_2</font> <font color="blue">gel_2</font> <font color="blue">electrophoresis_2</font> <font color="blue">._2</font> 
<br> RESULTS <font color="blue">The_1</font> <font color="blue">mean_4</font> <font color="blue">LDL_4</font> <font color="blue">size_4</font> <font color="blue">was_1</font> <font color="blue">significantly_1</font> <font color="blue">increased_2</font> <font color="blue">in_1</font> <font color="blue">all_1</font> <font color="blue">groups_1</font> <font color="blue">._1</font> <font color="blue">This_1</font> <font color="blue">change_1</font> <font color="blue">was_1</font> <font color="blue">more_1</font> <font color="blue">prominent_1</font> <font color="blue">with_1</font> <font color="blue">RF_1</font> than <font color="blue">with_1</font> <font color="blue">other_1</font> <font color="blue">treatments_1</font> <font color="blue">in_1</font> <font color="blue">parallel_1</font> with <font color="blue">its_1</font> <font color="blue">greater_1</font> <font color="blue">hypotriglyceridemic_2</font> <font color="blue">capacity_2</font> ( p < 0.05 <font color="blue">compared_1</font> <font color="blue">with_1</font> <font color="blue">R_1</font> <font color="blue">and_1</font> <font color="blue">Rω_1</font> <font color="blue">)_1</font> . A <font color="blue">decrease_3</font> <font color="blue">in_3</font> <font color="blue">insulin_5</font> <font color="blue">resistance_5</font> <font color="blue">by_3</font> <font color="blue">RF_3</font> was <font color="blue">also_1</font> <font color="blue">noted_1</font> <font color="blue">._1</font> <font color="blue">Only_1</font> <font color="blue">RF_1</font> <font color="blue">significantly_1</font> <font color="blue">raised_1</font> <font color="blue">HDL_4</font> <font color="blue">-_4</font> <font color="blue">C_4</font> <font color="blue">levels_4</font> ( by 7.7% , p < 0.05 ) <font color="blue">by_1</font> <font color="blue">increasing_1</font> <font color="blue">the_1</font> <font color="blue">cholesterol_2</font> <font color="blue">of_2</font> <font color="blue">small_2</font> <font color="blue">HDL_2</font> <font color="blue">particles_2</font> <font color="blue">._2</font> <font color="blue">The_1</font> <font color="blue">cholesterol_3</font> <font color="blue">of_3</font> <font color="blue">larger_4</font> <font color="blue">HDL_4</font> <font color="blue">subclasses_4</font> <font color="blue">was_1</font> <font color="blue">significantly_1</font> <font color="blue">increased_2</font> <font color="blue">by_1</font> <font color="blue">R_1</font> <font color="blue">and_1</font> <font color="blue">Rω._1</font> 
<br> CONCLUSIONS <font color="blue">All_1</font> <font color="blue">regimens_1</font> <font color="blue">increased_1</font> <font color="blue">mean_3</font> <font color="blue">LDL_3</font> <font color="blue">size_3</font> <font color="blue">;_3</font> <font color="blue">RF_1</font> <font color="blue">was_1</font> <font color="blue">the_1</font> <font color="blue">most_1</font> <font color="blue">effective_1</font> <font color="blue">._1</font> <font color="blue">A_1</font> <font color="blue">differential_1</font> <font color="blue">effect_1</font> <font color="blue">of_1</font> <font color="blue">treatments_1</font> <font color="blue">was_1</font> <font color="blue">noted_1</font> on <font color="blue">the_1</font> <font color="blue">HDL_2</font> <font color="blue">subfraction_2</font> <font color="blue">profile_1</font> <font color="blue">._1</font>